6 results on '"Ludwikowski B"'
Search Results
2. First genome-wide association study of esophageal atresia identifies three genetic risk loci at CTNNA3, FOXF1/FOXC2/FOXL1, and HNF1B
- Author
-
Gehlen, J., Giel, A.S., Köllges, R., Haas, S.L., Zhang, R., Trcka, J., Sungur, A., Renziehausen, F., Bornholdt, D., Jung, D., Hoyer, P.D., Nordenskjöld, A., Tibboel, D., Vlot, J., Spaander, M.C., Smigiel, R., Patkowski, D., Roeleveld, N., Rooij, I.A.L.M. van, Blaauw, I. de, Hölscher, A., Pauly, M., Leutner, A., Fuchs, J., Niethammer, J., Melissari, M.T., Jenetzky, E., Zwink, N., Thiele, H., Hilger, A.C., Hess, T., Trautmann, J., Marks, M., Baumgarten, M., Bläss, G., Landén, M., Fundin, B., Bulik, C.M., Pennimpede, T., Ludwig, M., Ludwig, K.U., Mangold, E., Heilmann-Heimbach, S., Moebus, S., Herrmann, B.G., Alsabeah, K., Burgos, C.M., Lilja, H.E., Azodi, S., Stenström, P., Arnbjörnsson, E., Frybova, B., Lebensztejn, D.M., Debek, W., Kolodziejczyk, E., Kozera, K., Kierkus, J., Kaliciński, P., Stefanowicz, M., Socha-Banasiak, A., Kolejwa, M., Piaseczna-Piotrowska, A., Czkwianianc, E., Nöthen, M.M., Grote, P., Rygl, M., Reinshagen, K., Spychalski, N., Ludwikowski, B., Hubertus, J., Heydweiller, A., Ure, B., Muensterer, O.J., Aubert, O., Gosemann, J.H., Lacher, M., Degenhardt, P., Boemers, T.M., Mokrowiecka, A., Małecka-Panas, E., Wöhr, M., Knapp, M., Seitz, G., Klein, A., Oracz, G., Brosens, E., Reutter, H., Schumacher, J., Gehlen, J., Giel, A.S., Köllges, R., Haas, S.L., Zhang, R., Trcka, J., Sungur, A., Renziehausen, F., Bornholdt, D., Jung, D., Hoyer, P.D., Nordenskjöld, A., Tibboel, D., Vlot, J., Spaander, M.C., Smigiel, R., Patkowski, D., Roeleveld, N., Rooij, I.A.L.M. van, Blaauw, I. de, Hölscher, A., Pauly, M., Leutner, A., Fuchs, J., Niethammer, J., Melissari, M.T., Jenetzky, E., Zwink, N., Thiele, H., Hilger, A.C., Hess, T., Trautmann, J., Marks, M., Baumgarten, M., Bläss, G., Landén, M., Fundin, B., Bulik, C.M., Pennimpede, T., Ludwig, M., Ludwig, K.U., Mangold, E., Heilmann-Heimbach, S., Moebus, S., Herrmann, B.G., Alsabeah, K., Burgos, C.M., Lilja, H.E., Azodi, S., Stenström, P., Arnbjörnsson, E., Frybova, B., Lebensztejn, D.M., Debek, W., Kolodziejczyk, E., Kozera, K., Kierkus, J., Kaliciński, P., Stefanowicz, M., Socha-Banasiak, A., Kolejwa, M., Piaseczna-Piotrowska, A., Czkwianianc, E., Nöthen, M.M., Grote, P., Rygl, M., Reinshagen, K., Spychalski, N., Ludwikowski, B., Hubertus, J., Heydweiller, A., Ure, B., Muensterer, O.J., Aubert, O., Gosemann, J.H., Lacher, M., Degenhardt, P., Boemers, T.M., Mokrowiecka, A., Małecka-Panas, E., Wöhr, M., Knapp, M., Seitz, G., Klein, A., Oracz, G., Brosens, E., Reutter, H., and Schumacher, J.
- Abstract
Item does not contain fulltext, Esophageal atresia with or without tracheoesophageal fistula (EA/TEF) is the most common congenital malformation of the upper digestive tract. This study represents the first genome-wide association study (GWAS) to identify risk loci for EA/TEF. We used a European case-control sample comprising 764 EA/TEF patients and 5,778 controls and observed genome-wide significant associations at three loci. On chromosome 10q21 within the gene CTNNA3 (p = 2.11 × 10(-8); odds ratio [OR] = 3.94; 95% confidence interval [CI], 3.10-5.00), on chromosome 16q24 next to the FOX gene cluster (p = 2.25 × 10(-10); OR = 1.47; 95% CI, 1.38-1.55) and on chromosome 17q12 next to the gene HNF1B (p = 3.35 × 10(-16); OR = 1.75; 95% CI, 1.64-1.87). We next carried out an esophageal/tracheal transcriptome profiling in rat embryos at four selected embryonic time points. Based on these data and on already published data, the implicated genes at all three GWAS loci are promising candidates for EA/TEF development. We also analyzed the genetic EA/TEF architecture beyond the single marker level, which revealed an estimated single-nucleotide polymorphism (SNP)-based heritability of around 37% ± 14% standard deviation. In addition, we examined the polygenicity of EA/TEF and found that EA/TEF is less polygenic than other complex genetic diseases. In conclusion, the results of our study contribute to a better understanding on the underlying genetic architecture of ET/TEF with the identification of three risk loci and candidate genes.
- Published
- 2022
3. MUC-FIRE: Study protocol for a randomized multicenter open-label controlled trial to show that MUCous FIstula REfeeding reduces the time from enterostomy closure to full enteral feeds.
- Author
-
Großhennig A, Wiesner S, Hellfritsch J, Thome U, Knüpfer M, Peter C, Metzelder M, Binder C, Wanz U, Flucher C, Brands BO, Mollweide A, Ludwikowski B, Koluch A, Scherer S, Gille C, Theilen TM, Rochwalsky U, Karpinski C, Schulze A, Schuster T, Weber F, Seitz G, Gesche J, Nissen M, Jäger M, Koch A, Ure B, Madadi-Sanjani O, and Lacher M
- Abstract
Background: After enterostomy creation, the distal bowel to the ostomy is excluded from the physiologic passage of stool, nutrient uptake, and growth of this intestinal section. Those infants frequently require long-term parenteral nutrition, continued after enterostomy reversal due to the notable diameter discrepancy of the proximal and distal bowel. Previous studies have shown that mucous fistula refeeding (MFR) results in faster weight gain in infants. The aim of the randomized multicenter open-label controlled MUC ous FI stula RE feeding (" MUC-FIRE ") trial is to demonstrate that MFR between enterostomy creation and reversal reduces the time to full enteral feeds after enterostomy closure compared to controls, resulting in shorter hospital stay and less adverse effects of parenteral nutrition. Methods/Design: A total of 120 infants will be included in the MUC-FIRE trial. Following enterostomy creation, infants will be randomized to either an intervention or a non-intervention group.In the intervention group, perioperative MFR between enterostomy creation and reversal will be performed. The control group receives standard care without MFR.The primary efficacy endpoint of the study is the time to full enteral feeds. Secondary endpoints include first postoperative bowel movement after stoma reversal, postoperative weight gain, and days of postoperative parenteral nutrition. In addition adverse events will be analyzed., Discussion: The MUC-FIRE trial will be the first prospective randomized trial to investigate the benefits and disadvantages of MFR in infants. The results of the trial are expected to provide an evidence-based foundation for guidelines in pediatric surgical centers worldwide., Trial Registration: The trial has been registered at clinicaltrials.gov (number: NCT03469609, date of registration: March 19, 2018; last update: January 20, 2023, https://clinicaltrials.gov/ct2/show/NCT03469609?term=NCT03469609&draw=2&rank=1)., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
4. First genome-wide association study of esophageal atresia identifies three genetic risk loci at CTNNA3 , FOXF1 / FOXC2 / FOXL1 , and HNF1B .
- Author
-
Gehlen J, Giel AS, Köllges R, Haas SL, Zhang R, Trcka J, Sungur AÖ, Renziehausen F, Bornholdt D, Jung D, Hoyer PD, Nordenskjöld A, Tibboel D, Vlot J, Spaander MCW, Smigiel R, Patkowski D, Roeleveld N, van Rooij IA, de Blaauw I, Hölscher A, Pauly M, Leutner A, Fuchs J, Niethammer J, Melissari MT, Jenetzky E, Zwink N, Thiele H, Hilger AC, Hess T, Trautmann J, Marks M, Baumgarten M, Bläss G, Landén M, Fundin B, Bulik CM, Pennimpede T, Ludwig M, Ludwig KU, Mangold E, Heilmann-Heimbach S, Moebus S, Herrmann BG, Alsabeah K, Burgos CM, Lilja HE, Azodi S, Stenström P, Arnbjörnsson E, Frybova B, Lebensztejn DM, Debek W, Kolodziejczyk E, Kozera K, Kierkus J, Kaliciński P, Stefanowicz M, Socha-Banasiak A, Kolejwa M, Piaseczna-Piotrowska A, Czkwianianc E, Nöthen MM, Grote P, Rygl M, Reinshagen K, Spychalski N, Ludwikowski B, Hubertus J, Heydweiller A, Ure B, Muensterer OJ, Aubert O, Gosemann JH, Lacher M, Degenhardt P, Boemers TM, Mokrowiecka A, Małecka-Panas E, Wöhr M, Knapp M, Seitz G, de Klein A, Oracz G, Brosens E, Reutter H, and Schumacher J
- Abstract
Esophageal atresia with or without tracheoesophageal fistula (EA/TEF) is the most common congenital malformation of the upper digestive tract. This study represents the first genome-wide association study (GWAS) to identify risk loci for EA/TEF. We used a European case-control sample comprising 764 EA/TEF patients and 5,778 controls and observed genome-wide significant associations at three loci. On chromosome 10q21 within the gene CTNNA3 (p = 2.11 × 10
-8 ; odds ratio [OR] = 3.94; 95% confidence interval [CI], 3.10-5.00), on chromosome 16q24 next to the FOX gene cluster (p = 2.25 × 10-10 ; OR = 1.47; 95% CI, 1.38-1.55) and on chromosome 17q12 next to the gene HNF1B (p = 3.35 × 10-16 ; OR = 1.75; 95% CI, 1.64-1.87). We next carried out an esophageal/tracheal transcriptome profiling in rat embryos at four selected embryonic time points. Based on these data and on already published data, the implicated genes at all three GWAS loci are promising candidates for EA/TEF development. We also analyzed the genetic EA/TEF architecture beyond the single marker level, which revealed an estimated single-nucleotide polymorphism (SNP)-based heritability of around 37% ± 14% standard deviation. In addition, we examined the polygenicity of EA/TEF and found that EA/TEF is less polygenic than other complex genetic diseases. In conclusion, the results of our study contribute to a better understanding on the underlying genetic architecture of ET/TEF with the identification of three risk loci and candidate genes., Competing Interests: The co-author C.M.B. declares the following interests: Shire (grant recipient, Scientific Advisory Board member), Idorsia (consultant), Lundbeckfonden (grant recipient), Pearson (author, royalty recipient), and Equip Health Inc. (Clinical Advisory Board). All other co-authors declare no competing interests., (© 2022 The Authors.)- Published
- 2022
- Full Text
- View/download PDF
5. Diagnosis and Therapy of Female Genital Malformations (Part 2). Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/052, May 2019).
- Author
-
Oppelt P, Binder H, Birraux J, Brucker S, Dingeldein I, Draths R, Eckoldt F, Füllers U, Hiort O, Hoffmann D, Hoopmann M, Hucke J, Korell M, Kühnert M, Ludwikowski B, Mentzel HJ, Mon OʼDey D, Rall K, Riccabona M, Rimbach S, Schäffeler N, Shavit S, Stein R, Utsch B, Wenzl R, Wieacker P, and Zeino M
- Abstract
Objectives Female genital malformations may be present in the form of individual entities, they may involve neighboring organs or they may occur in the context of complex syndromes. Given the anatomical structures of the vulva, vagina, uterus and uterine appendages, the clinical picture of malformations varies greatly. Methods This S2k-guideline was developed by representative members from different medical specialties and professions as part of the guidelines program of the DGGG, SGGG and OEGGG. The recommendations and statements were developed and voted on using a structured consensus process with neutral moderation. Recommendations This guideline is the first comprehensive summary of female genital malformations from infancy to adulthood which covers clinical examinations, diagnostic workups and treatment options. Additional chapters have been included on complex urogenital malformations, vascular malformations, psychosomatic care, and tumor risk., Competing Interests: Conflict of Interest/Interessenkonflikt The conflicts of interest of all of the authors are listed in the German-language long version of the guideline./Die Interessenkonflikte der Autoren sind in der Langfassung der Leitlinie aufgelistet., (Thieme. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
6. Diagnosis and Therapy of Female Genital Malformations (Part 1). Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/052, May 2019).
- Author
-
Oppelt P, Binder H, Birraux J, Brucker S, Dingeldein I, Draths R, Eckoldt F, Füllers U, Hiort O, Hoffmann D, Hoopmann M, Hucke J, Korell M, Kühnert M, Ludwikowski B, Mentzel HJ, Mon OʼDey D, Rall K, Riccabona M, Rimbach S, Schäffeler N, Shavit S, Stein R, Utsch B, Wenzl R, Wieacker P, and Zeino M
- Abstract
Objectives Female genital malformations may take the form of individual entities, they may involve neighboring organs or they may occur in the context of complex syndromes. Given the anatomical structures of the vulva, vagina, uterus and adnexa, the clinical picture of malformations may vary greatly. Depending on the extent of the malformation, organs of the urinary system or associated malformations may also be involved. Methods This S2k-guideline was developed by representative members from different medical specialties and professions as part of the guidelines program of the DGGG, SGGG and OEGGG. The recommendations and statements were developed using a structured consensus process with neutral moderation and voted on. Recommendations The guideline is the first comprehensive presentation of the symptoms, diagnosis and treatment options for female genital malformations. Additional chapters on classifications and transition were included., Competing Interests: Conflict of Interest/Interessenkonflikt The conflicts of interest of all of the authors are listed in the German-language long version of the guideline./Die Interessenkonflikte der Autoren sind in der Langfassung der Leitlinie aufgelistet., (Thieme. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.